Sarah Romano - Dec 29, 2023 Form 4 Insider Report for First Wave BioPharma, Inc. (FWBI)

Role
Chief Financial Officer
Signature
/s/ Sarah Romano
Stock symbol
FWBI
Transactions as of
Dec 29, 2023
Transactions value $
$0
Form type
4
Date filed
1/3/2024, 07:54 PM
Previous filing
Oct 6, 2023
Next filing
Jan 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FWBI Common Stock Award $0 +12.6K +1596.71% $0.00 13.4K Dec 29, 2023 Direct F1, F3
transaction FWBI Common Stock Award $0 +7K +52.22% $0.00 20.4K Jan 2, 2024 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 29, 2023, the Reporting Person was granted 12,614 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest upon closing of the Issuer's proposed acquisition of ImmunogenX, Inc.
F2 On January 2, 2024, the Reporting Person was granted 7,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.
F3 Includes unvested RSUs.